Tearsolutions Incis A Delawarecorporation Based In Charlottesvilleva Thecompany Has Successfully Completed A Well Powered 204 Patient Phaseii Proof Of Concept Clinical Trial For Thetreatment Of Ocular Surfacediseasein Primary Sja Gren S Syndromepatientsstatistically Significant Improvement In Both Sign And Symptom At Two Weeks Was Found Thetrial Compared Vehicleand Two Doses Of Lacripeptma Novel 19 Aa Peptidethat Is Present In Normal Tears And Deficient In All Forms Of Dry Eyethepeptiderestores Homeostasis To Theocular Surfacein Particular Thebarrier Function Of Thecorneal Epithelium And Normal Function Of Sensory Nerves At Thecorneal Surfacein Preclinical Animal Models Restoration Of Epithelial Barrier Function Can Bemeasured Clinically As A Decreasein Corneal Fluorescein Staining Whiletheimprovement In Sensory Nervefunction Restores Normal Production Of Thecomponents Of Tearstheaqueous Via Reinnervation Of Lacrimal Glandsthelipid Via Reinnervation Of Meibomium Glands And Themucin Via Reinnervation Of Goblet Cells Improvement In Fluorescein Staining And Tear Productionschirmer Tear Testareclinical Ae Signsof Ocular Sufacediseasethat Havebeen Used In Thefda Approval Of Xiidra And Restasisrespectively Lacripep Was Discovered At Theuniversity Of Virginia With Nih National Eyeinstitutefunding As A Naturally Occurring Fragment Of Thelarger 119 Aa Proteinlacritinin An Unbiased Screen For Novel Factors Capableof Addressing Dry Eyemanagement Teamceo Presidentanil Asraniexecutivechairrobert Dempseycso Cofoundergordon Wlauriephdfarvocfocolin Mrolphchief Regulatory Officermichellecarpenter Jdracchief Medical Officermarc Godrichmdsecretarymac Thompsonlldfor Moreinformation Pleasevisit Www Tearsolutions Com
